-

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 - Règlement Général de l’Autorité des marchés financiers

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Voting rights:

Date

Total number of shares of Theraclion

Total number of theoretical voting rights of Theraclion (1)

Total number of real voting rights of Theraclion (2)

30/06/2026

73 123 311

89 137 355

87 570 061

(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation

(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.
Theraclion is developing Sonovein®, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein® is not yet available for sale.

Based in Malakoff (Paris), the Theraclion team consists of approximately 35 people.

For more information, please visit www.theraclion.com and follow us on LinkedIn.

Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402
LEI: 9695007X7HA7A1GCYD29

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
contact@theraclion.com

Theraclion

BOURSE:ALTHE

Release Versions

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
contact@theraclion.com

More News From Theraclion

2026 Half-Year Results: Theraclion Prepares for a New Stage in Its Development

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today reports its results for the first half ended 30 June 2026, approved by the Board of Directors on 15 September 2026, ahead of the FDA decision on the De Novo submission for Sonovein®, expected between the end of the third quarter and the...

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Theraclion (Paris:ALTHE): Listed on Euronext Growth Paris PEA PME eligible ISIN Code : FR0010120402 Website : www.theraclion.com Voting rights : Date Total number of shares of Theraclion Total number of theoretical voting rights of Theraclion (1) Total number of real voting rights of Theraclion (2) 31/07/2026 73 543 457 88 767 504 86 957 843 (1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are atta...

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026. By the end of the first half of 2026, Theraclion's commercial acceleration is beginning to show clearly across every stage of the sales cycle. This momentum has been accompanied by signifi...
Back to Newsroom